Post-earnings recap
Reported
Mon, Nov 3, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Neurocrine Biosciences reported a loss per share of $0.21, which did not meet any consensus expectations, leading to a 2% decline in stock price. The lack of revenue figures and guidance contributed to investor uncertainty. Overall, the market reacted negatively as investors seek clearer insights into the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | +0.00% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding future performance without offering specific guidance. They emphasized the importance of their current projects.
Management did not provide specific guidance for future quarters.
The company is focusing on ongoing projects and pipeline development.